In July 2025, China’s National Health Commission banned routine clinical use of deep cervical lymphatic-venous anastomosis (dcLVA), an experimental neck surgery marketed as a treatment for Alzheimer’s disease, citing a lack of robust clinical evidence. A BMJ investigation reports that the procedure’s inventor, Hangzhou microsurgeon Qingping Xie, has since been detained. Neither the grounds for the detention nor its current status have been publicly detailed in reporting available at time of writing. What has not stopped is the underlying research: dcLVA trials remain registered, and in at least one case are actively recruiting outside China, on the same limited evidence base that triggered the domestic ban.
For research-integrity offices, IRBs and ethics boards evaluating protocols that build on dcLVA, this is an unusual case to reason about: the country of origin has simultaneously restricted the procedure’s clinical use at home and detained the person who invented it, while the science underneath — thin, uncontrolled, single-arm case series — is identical wherever the surgery is performed.
What dcLVA claims to do
Deep cervical lymphatic-venous anastomosis is a microsurgical procedure that connects lymphatic vessels to veins in the neck, performed under a surgical microscope with fluorescent tracers to visualize the lymphatic channels, typically over two to three hours under general anesthesia. The rationale draws on relatively recent findings about meningeal lymphatic vessels, which drain cerebrospinal fluid into the deep cervical lymph nodes as part of the brain’s broader glymphatic clearance system — the pathway thought to help clear amyloid-beta and tau aggregates implicated in Alzheimer’s disease. The theory behind dcLVA is that age-related sluggishness in this drainage route contributes to protein buildup, and that surgically rerouting lymphatic flow into the venous system eases outflow from the brain. This remains a theoretical mechanism; it has not been established that the surgery produces the drainage improvement it is premised on, let alone that improved drainage changes the course of Alzheimer’s disease.
Qingping Xie, a microsurgeon and hospital president at Hangzhou Qiushi Hospital, performed the first dcLVA procedure on an Alzheimer’s patient around 2020 after obtaining his own hospital’s ethical approval. The procedure spread rapidly across Chinese hospitals over the following years, drawing wider international attention after being covered in Science in 2025 and Nature in 2026. By the time of the 2025 ban, reporting on the Chinese government’s action described the surgery as having been adopted at several hundred hospitals nationwide.
Why China banned routine use
China’s National Health Commission banned dcLVA for routine clinical use in July 2025, citing insufficient clinical evidence of safety and efficacy. Coverage of the ban, including reporting from the South China Morning Post, describes the restriction as applying to the surgery’s use as a marketed clinical treatment outside formal research protocols; use within registered clinical trials was not prohibited. The evidence base the ban responded to consisted, at that point, of case reports and single-center case series without control groups, blinding, or long-term follow-up — the pattern the wider neurology and neurosurgery literature has flagged as inadequate to support a causal claim of benefit. Commentary summarized by Alzforum characterizes existing dcLVA results as, at most, hypothesis-generating, with named researchers in the field calling for randomized, multicenter trials with standardized imaging before any conclusion about efficacy is warranted.
The detention — what is and isn’t known
The BMJ’s investigation states that Xie has been detained, but the publicly available reporting reviewed for this article does not specify the date of detention, the legal or administrative grounds cited, the detaining authority, or Xie’s current custody status. No public statement attributed to Xie or Hangzhou Qiushi Hospital in response to the detention was located in the sources reviewed. Readers should treat the detention as a reported fact from a single investigative source, pending further detail, rather than as an adjudicated finding of wrongdoing — nothing in the coverage available at time of writing establishes what, if anything, Xie has been formally accused of.
The trials that are still going ahead
Despite the domestic ban on routine clinical use, dcLVA research has continued under China’s research-trial exemption, and separately, at least one trial is recruiting outside China. Registered studies identified on ClinicalTrials.gov include:
| Trial | Registration | Sponsor / site | Notes |
|---|---|---|---|
| CLEAN-AD | NCT07073066 | Beijing Tiantan Hospital, led by Yilong Wang | Multicenter, ~376 participants planned across 20 centers in China |
| Multicenter RCT of deep jugular lymphovenous anastomosis | NCT07060391 | China (multi-site) | ~186 participants planned |
| Pilot study of dcLVA | NCT06448442 | Second Affiliated Hospital, Zhejiang University School of Medicine | Single-site pilot, registered 2024 |
| CLIVA-AD | NCT07294885 | Not independently confirmed | Reported by Alzforum to include a sham-surgery control arm; ~50 participants |
| Yale-led proof-of-concept | NCT06965062 | Yale-affiliated, recruiting in Singapore | Outside China; the clearest example of dcLVA research proceeding internationally after the domestic ban |
The China-registered trials continue under the research exemption China’s own ban carved out — they are not, in that narrow sense, defying the ban. The Singapore-recruiting, Yale-affiliated trial is the more consequential case for research oversight bodies outside China: it is proceeding on the same underlying evidence base — uncontrolled case series generated in China before the ban — under a separate country’s ethical review, without the domestic regulatory action or the detention of the procedure’s originator necessarily entering that review in a formal way.
The governance question for research oversight bodies
Neither a foreign government’s ban nor the detention of a researcher is, by itself, evidence about whether a procedure works or is safe — bans can be issued for reasons unrelated to the underlying science, and detentions can reflect matters entirely separate from a study’s scientific merits, including matters never made public. Equally, neither fact is something an IRB or research ethics committee reviewing a dcLVA protocol should treat as background noise. A few considerations follow directly from established human-subjects research oversight principles rather than from any conclusion about this specific case:
- The evidence base doesn’t change at the border. The case-series-only evidence that led China’s National Health Commission to restrict routine use is the same evidence base any other country’s trial protocol is built on. A reviewing IRB’s risk-benefit analysis should weigh that evidentiary gap on its own terms, independent of what any government has decided to do about it domestically.
- Disclosure to participants matters. Where a sponsor or investigator is aware of a domestic regulatory restriction on the procedure at its site of origin, or of unresolved questions about the original investigator, established informed-consent norms (reflected across ICH E6 good clinical practice guidance and comparable national frameworks) point toward disclosing that context to prospective participants as part of an honest description of the state of the evidence, not just the study’s own protocol.
- A ban on routine use is not evidence about a specific trial’s design. China’s restriction targeted uncontrolled clinical deployment, not the research exemption itself. A reviewing body elsewhere should scrutinize the specific protocol in front of it — control arm, blinding, endpoints, stopping rules — rather than either dismissing the foreign ban as irrelevant or treating it as a shortcut verdict on trials it doesn’t actually describe.
- Detention of an originating investigator is a reason to look harder, not to look away. Where the facts underlying a detention are undisclosed, a research oversight body cannot respond to it, but it can decline to treat the originator’s institutional standing or prior ethical approvals as reliable inputs to its own review until more is known.
Sources
This article draws on the BMJ’s investigative report (BMJ 2026;394:bmj-2026-100302), Alzforum’s research summary published 16 January 2026, and the South China Morning Post’s coverage of the July 2025 ban, cross-checked against trial registrations on ClinicalTrials.gov. Facts not confirmed across at least one of these sources are described in this article as reported rather than established.
